Adagene Inc ADR (ADAG) Stock Price, Quote & News

Company Profile

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/met...

Industry: Biotechnology

Sector: Healthcare

Phone: 86 512 8777 3632

Website: www.adagene.com

Address:

Building C14, 4th Floor No. 218, Xinghu Street Suzhou Industrial Park, Suzhou, China

psw_psw Nov. 13 at 2:45 PM

$ADAG huge news, wake up folks

1 · Reply

topstockalerts Nov. 11 at 6:25 PM

Top Gainers PT2 $KLTR $RDGT $ADAG $XBIT $NRGV

0 · Reply

dbr_island Nov. 11 at 2:52 PM

$ADAG there it goes…… Now calling 🚨SDA🚨as I’m hearing they will be announcing something soon I am even willing to use my COIN TSLA profits into SDA

1 · Reply

intrader Nov. 11 at 2:50 PM

$ADAG

1 · Reply

intrader Nov. 11 at 2:43 PM

$ADAG I'm in at $1.74

0 · Reply

dbr_island Nov. 10 at 6:35 PM

$ADAG there it goes Now calling 🚨SDA🚨as I’m hearing they will be announcing something soon I am even willing to use my COIN TSLA profits into SDA

0 · Reply

lousjamsession Nov. 10 at 3:46 PM

$ADAG all ... green

0 · Reply

BEATOFtheMARKET Oct. 24 at 9:51 PM

$ACLX $ACN $ADAG $ADCT $AER 10/10 to 10/24 list results 🔥 Cycle Trading Signal plugged into AI 🔥

0 · Reply

NVDAMillionaire Oct. 3 at 9:11 AM

$ADAG Excellent article that nails exactly where ADAG stands right now. So if you want to update your ADAG knowledge or get acquainted with ADAG, this is a must read. https://beyondspx.com/quote/ADAG/analysis/adagene-unmasking-precision-in-oncology-immunotherapy-nasdaq-adag

0 · Reply

JarvisFlow Sep. 18 at 12:30 PM

LUCID CAPITAL MARKETS has updated their rating for Adagene ( $ADAG ) to Buy with a price target of 9.

0 · Reply

Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Oct 31, 2025, 7:00 AM EDT - 16 days ago

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

Sep 16, 2025, 8:00 AM EDT - 2 months ago

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

Sep 5, 2025, 9:55 AM EDT - 2 months ago

Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China

Sep 3, 2025, 9:05 AM EDT - 2 months ago

Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

Aug 26, 2025, 8:05 AM EDT - 2 months ago

Adagene to Participate in Two Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 3 months ago

Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates

Jul 15, 2025, 7:00 AM EDT - 4 months ago

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

Jul 8, 2025, 7:00 AM EDT - 4 months ago

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

Jul 1, 2025, 7:00 AM EDT - 4 months ago

Adagene announces up to $25 million strategic investment from Sanofi

May 27, 2025, 7:30 AM EDT - 6 months ago

Adagene to Present at Jefferies Global Healthcare Conference 2025

May 22, 2025, 5:05 PM EDT - 6 months ago

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 7 months ago

Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

Apr 23, 2025, 10:05 AM EDT - 7 months ago

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 24, 2025, 8:00 AM EDT - 8 months ago

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 13, 2025, 8:00 AM EDT - 8 months ago

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

Mar 6, 2025, 8:00 AM EST - 9 months ago

Adagene to Present at Leerink's Global Healthcare Conference 2025

Feb 27, 2025, 8:00 AM EST - 9 months ago

Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer

Jan 29, 2025, 6:14 AM EST - 10 months ago

CD47 Inhibitor Drug Clinical Trials Market Opportunity Outlook 2028, Competitive Analysis of Adagene, ALX, ImmuneOncia, ImmuneOnco, Light Chain Bioscience, Phanes, and Virtuoso,

Jan 21, 2025, 5:00 PM EST - 10 months ago

Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium

Nov 7, 2024, 10:01 AM EST - 1 year ago

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 9, 2024, 6:00 AM EDT - 1 year ago

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Sep 16, 2024, 3:01 AM EDT - 1 year ago

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Jul 12, 2024, 7:00 AM EDT - 1 year ago

Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September

May 22, 2024, 4:45 PM EDT - 1 year ago

Adagene to Present at Investor Conferences in June

Mar 29, 2024, 9:00 AM EDT - 1 year ago

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 7, 2024, 4:01 PM EST - 1 year ago

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

Feb 27, 2024, 8:00 AM EST - 1 year ago

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024

Feb 9, 2024, 6:00 AM EST - 1 year ago

Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabl

Jan 16, 2024, 5:01 PM EST - 1 year ago

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Jan 4, 2024, 5:00 AM EST - 2 years ago

Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023

Oct 12, 2023, 8:00 AM EDT - 2 years ago

Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Sep 7, 2023, 6:00 AM EDT - 2 years ago

Adagene to Present at Investor and Scientific Conferences in September

Aug 31, 2023, 7:32 AM EDT - 2 years ago

Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update

May 4, 2023, 9:00 AM EDT - 2 years ago

Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate

Apr 28, 2023, 7:00 AM EDT - 2 years ago

Adagene Announces Updates to its Board of Directors

Apr 18, 2023, 9:17 AM EDT - 2 years ago

Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors

Mar 28, 2023, 4:30 PM EDT - 2 years ago

Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 14, 2023, 6:00 PM EDT - 2 years ago

Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April

Mar 5, 2023, 7:39 PM EST - 2 years ago

Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board

Jan 9, 2023, 7:00 AM EST - 3 years ago

Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial

Jan 5, 2023, 4:01 PM EST - 3 years ago

Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9

Dec 16, 2022, 6:30 AM EST - 3 years ago

Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche's Standard-of-Care for First-Line Advanced Liver Cancer

Nov 21, 2022, 4:05 PM EST - 3 years ago

Adagene Appoints Cuong Do to Board of Directors and Audit Committee

Nov 10, 2022, 9:05 AM EST - 3 years ago

Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors

Oct 11, 2022, 4:03 PM EDT - 3 years ago

Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer's (SITC) Annual Meeting in November

Sep 10, 2022, 4:13 AM EDT - 3 years ago

Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors

Aug 30, 2022, 5:25 PM EDT - 3 years ago

Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates

Jun 29, 2022, 4:05 PM EDT - 3 years ago

Adagene Announces Authorization of Share Repurchase Program up to US$10 Million

psw_psw Nov. 13 at 2:45 PM

$ADAG huge news, wake up folks

1 · Reply

topstockalerts Nov. 11 at 6:25 PM

Top Gainers PT2 $KLTR $RDGT $ADAG $XBIT $NRGV

0 · Reply

dbr_island Nov. 11 at 2:52 PM

$ADAG there it goes…… Now calling 🚨SDA🚨as I’m hearing they will be announcing something soon I am even willing to use my COIN TSLA profits into SDA

1 · Reply

intrader Nov. 11 at 2:50 PM

$ADAG

1 · Reply

intrader Nov. 11 at 2:43 PM

$ADAG I'm in at $1.74

0 · Reply

dbr_island Nov. 10 at 6:35 PM

$ADAG there it goes Now calling 🚨SDA🚨as I’m hearing they will be announcing something soon I am even willing to use my COIN TSLA profits into SDA

0 · Reply

lousjamsession Nov. 10 at 3:46 PM

$ADAG all ... green

0 · Reply

BEATOFtheMARKET Oct. 24 at 9:51 PM

$ACLX $ACN $ADAG $ADCT $AER 10/10 to 10/24 list results 🔥 Cycle Trading Signal plugged into AI 🔥

0 · Reply

NVDAMillionaire Oct. 3 at 9:11 AM

0 · Reply

JarvisFlow Sep. 18 at 12:30 PM

LUCID CAPITAL MARKETS has updated their rating for Adagene ( $ADAG ) to Buy with a price target of 9.

0 · Reply

BioTuesdays Sep. 16 at 7:08 PM

$ADAG has announced an amendment to the 2021 collaboration and license agreement with Exelixis (Nasdaq: EXEL) to enable the development of a third novel masked monoclonal antibody (mAb) drug conjugate https://biotuesdays.com/2025/09/16/adagene-exelixis-amend-license-agreement-to-develop-third-masked-mab/

0 · Reply

BiotechBagholder Sep. 11 at 7:09 PM

$ADAG Can anyone share the CSCO abstracts and posters?

0 · Reply

kshonstocks Sep. 9 at 2:25 PM

$ADAG on scans, like chart, taking some

0 · Reply

DARKP00L Sep. 5 at 2:05 PM

$ADAG 10:02 on Sep. 05 2025 Adagene's Masked CTLA-4 Antibody ADG126 To Be Highlighted In Dual Oral Presentations At 2025 CSCO Meeting; Data Highlights Include Phase 1b/2 Results In MSS CRC And Combination With Pembrolizumab #tradeideas

0 · Reply

BioTuesdays Sep. 3 at 2:07 PM

$ADAG has announced the appointment of immuno-oncology pioneer, Axel Hoos, MD, PhD, as executive advisor. https://biotuesdays.com/2025/09/03/adagene-appoints-dr-axel-hoos-as-executive-advisor/

0 · Reply

TheRealShortSqueezy Sep. 2 at 5:06 PM

⏳Medicus Pharma ( $MDCX ) is gaining upward momentum, trading around $2.03 following this morning’s news ⏳ 🤝Today, the company finalized the acquisition of Antev Ltd., adding Teverelix, a next‑generation GnRH antagonist targeting acute urinary retention and high‑CV‑risk prostate cancer—unlocking a $6B+ market opportunity 🎯 This strategic addition bolsters their Phase 2 pipeline and elevates Medicus’s clinical and commercial potential, especially with veteran pharma leader Patrick J. Mahaffy joining the board. 📈Shares are reacting positively—this upward drift suggests growing investor confidence as key catalysts unfold. Levels: 2.09$➡ 2.28$ ➡ 2.46$ ➡ 2.59$ ➡ 2.67$ Website: https://medicuspharma.com Communicated Disclaimer : https://tinyurl.com/2afx6epb Peers: $CRBP $SKYE $ADAG $COYA #Advertisement

2 · Reply

TheRealShortSqueezy Sep. 2 at 1:48 PM

$MDCX On the verge of a breakout after that game-changing news hit this morning. 🚀2.05$ breakout is key !! 🚨 Medicus Pharma ($MDCX) has officially closed the acquisition of Antev Ltd., bringing in Teverelix — a next-gen GnRH antagonist with blockbuster potential. Teverelix is positioned as a first-in-class treatment for acute urinary retention (AURr) and a best-in-class option for advanced prostate cancer patients with high cardiovascular risk. Together, these indications represent a $6B+ market opportunity. Adding to the excitement, veteran pharma executive Patrick J. Mahaffy (ex-Clovis, ex-Pharmion) has joined the board, strengthening leadership as $MDCX advances multiple Phase 2b trials. This deal supercharges Medicus’s pipeline and sets the stage for major near-term catalysts. 🚀📈 Website: https://medicuspharma.com Communicated Disclaimer : https://tinyurl.com/2afx6epb Peers: $CRBP $SKYE $ADAG $COYA

1 · Reply

TheRealShortSqueezy Sep. 2 at 11:59 AM

🚨👇🏽Bottomed low float BIO ready to reverse 👇🏽🚨 ➡➡ Medicus Pharma Ltd ( Nasdaq : $MDCX ) ⬅⬅ Medicus Pharma is a biotech advancing disruptive therapies through partnerships, acquisitions, and in-house programs. Key Catalysts Ahead: 1️⃣Phase II SKNJCT-003: Interim data shows 60%+ lesion clearance with the D-MNA patch; trial expanded to 90 patients across U.S. & EU sites. 2️⃣FDA Type C Meeting (Q4 2025): Potential fast-track path toward NDA filing. 3️⃣Antev Acquisition: Adds Teverelix, targeting the $15B prostate cancer market. 4️⃣Veterinary Oncology: FDA MUMS designation opens a $250M+ equine cancer market with little competition. 📈The chart is forming a strong multi-bottom base on the daily. A breakout above $2.10 could trigger a momentum shift to the upside. Website: https://medicuspharma.com/ Communicated Disclaimer : https://tinyurl.com/2afx6epb Peers: $CRBP $SKYE $ADAG $COYA

0 · Reply

shawky1 Aug. 28 at 2:19 PM

$ADAG

0 · Reply

shawky1 Aug. 28 at 12:11 PM

$ADAG +2.50

0 · Reply

_www_larval_com_ Aug. 15 at 7:57 PM

$CUPR 10%[-87%] $CASI -8%[23%] $MAGH -7%[-62%] $TIVC -6%[1%] $ADAG -5%[-15%] most notable movement into the final minutes of trading.

0 · Reply

JarvisFlow Aug. 15 at 11:30 AM

HC Wainwright & Co. has adjusted their stance on Adagene ( $ADAG ), setting the rating to Buy with a target price of 8 → 7.

0 · Reply

Market Cap	86.25M
Revenue (ttm)	100,000.00
Net Income (ttm)	-33.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-33,420.00%
Debt to Equity Ratio	0.12

Volume	31,100
Avg Vol	89,412
Day's Range	N/A - N/A
Shares Out	47.13M
Stochastic %K	74%
Beta	0.73
Analysts	Sell
Price Target	$5.83